Does estradiol really protect your brain and bones during menopause?

What did @healing.endo.meno actually say?

The creator laid out a symptom-based and lab-based framework for identifying low estrogen. She named symptoms including "dry skin, dry eyes, hair loss, brain fog, mood swings, vaginal trophy, UTIs" and joint pain. Then she gave specific numeric thresholds: FSH below 10 means you're still producing enough, above 10 signals perimenopause, above 25 signals post-menopause. For estradiol, she said you want levels "at least at a 60" for bone and brain protection. She also pushed for tracking blood work before and during therapy, and finding a provider who does that monitoring. That last part is genuinely good advice. The numbers are where things get more complicated.

Does the science back this up?

Partially, but the FSH cutoffs she gives are not standard clinical thresholds, and the "estradiol at 60" target is oversimplified. The Menopause Society (formerly NAMS) does not define perimenopause by a single FSH value. FSH is notoriously variable during perimenopause, fluctuating day to day and across a cycle. A 2018 paper by Harlow et al. in the journal Menopause outlined the STRAW+10 staging criteria, which uses FSH trends and menstrual cycle irregularity together, not a single cutoff number. Saying FSH over 10 means you're "going into perimenopause" will alarm a lot of people who are just in the luteal phase of a normal cycle, where FSH can easily exceed 10 IU/L. On estradiol targets, the Women's Health Initiative Memory Study (Espeland et al., 2004, JAMA) and subsequent bone density research do suggest that physiological estradiol levels support bone mineral density and may have neuroprotective effects, but a specific floor of 60 pg/mL is not a universally endorsed clinical target. It is within a range some clinicians use, but presenting it as a hard threshold overstates the certainty.

What did they get wrong (or right)?

The symptom list is largely accurate. Estrogen decline is associated with vasomotor symptoms, genitourinary syndrome of menopause (which includes the "vaginal atrophy" she mispronounced as "trophy"), recurrent UTIs, mood disruption, joint discomfort, and cognitive changes. Research by Mosconi et al. (2021, Scientific Reports) does support a link between declining estradiol and changes in brain metabolism during the menopause transition, so the brain claim has real evidence behind it. The bone connection is well established. Where she goes wrong is treating FSH as a simple binary diagnostic tool with clean cutoffs. FSH above 10 does not reliably mean perimenopause in isolation. It must be interpreted alongside cycle history and clinical context. The "above 25 means post-meno" figure is also loose. Most labs use FSH above 25-40 IU/L in the context of amenorrhea and symptoms as suggestive of menopause, but a single draw is not conclusive. The North American Menopause Society recommends clinical diagnosis, not a number alone. Her advice to get estradiol tested specifically, rather than total estrogens, is actually correct and worth credit. Estradiol (E2) is the clinically relevant biomarker here.

What should you actually know?

FSH and estradiol levels are useful data points, but they require context that a TikTok video cannot provide. FSH varies significantly across the menstrual cycle, across days, and in response to stress. A single FSH of 12 IU/L in a 44-year-old with irregular cycles means something different than the same number in a 28-year-old with no symptoms. Estradiol targets in hormone therapy are individualized. Some clinicians aim for levels that relieve symptoms rather than hitting a specific number, and what works for bone protection may differ from what addresses vasomotor symptoms. The NAMS 2022 position statement is clear that hormone therapy is appropriate for many symptomatic women under 60 or within 10 years of menopause onset, but dosing and monitoring should be individualized. The creator's core message, that you should know your symptoms, get specific labs, and work with a provider who tracks your levels over time, is reasonable public health messaging. The specific numbers she gave should not be used as self-diagnosis tools.